Quantcast

Latest Histone deacetylase Stories

kidney stone
2014-08-18 03:45:20

Caroline Arbanas, Washington University in St. Louis Anyone who has suffered from kidney stones is keenly aware of the lack of drugs to treat the condition, which often causes excruciating pain. A new mouse study, however, suggests that a class of drugs approved to treat leukemia and epilepsy also may be effective against kidney stones, researchers at Washington University School of Medicine in St. Louis report. The drugs are histone deacetylase inhibitors, or HDAC inhibitors for...

2014-08-11 08:28:56

SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL). In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome (MDS). Orphan drug designation is also being sought for bladder cancer patients with specific genetic alterations. Mocetinostat is being...

2014-07-23 23:22:00

Transparency Market Research has added a new report titled "Histone Deacetylase Inhibitors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/histone-deacetylase-inhibitors.html. (PRWEB) July 22, 2014 Histone deacetylase (HDAC) are enzymes which remove acetyl groups from an N-acetyl lysine amino acid present on a histone, thus wrapping the DNA tightly by...

2014-06-03 23:09:20

Inhibiting enzymes that cause changes in gene expression could decrease chemotherapy resistance in ovarian cancer patients, researchers at Georgia State University and the University of Georgia say. Atlanta, Georgia (PRWEB) June 03, 2014 Inhibiting enzymes that cause changes in gene expression could decrease chemotherapy resistance in ovarian cancer patients, researchers at Georgia State University and the University of Georgia say. Dr. Susanna Greer, associate professor of biology, and...

2014-05-05 10:12:05

Inhibiting enzymes that cause changes in gene expression could decrease chemotherapy resistance in ovarian cancer patients, researchers at Georgia State University and the University of Georgia say. Dr. Susanna Greer, associate professor of biology, and research partners at the University of Georgia have identified two enzymes that suppress proteins that are important for regulating cell survival and chemoresistance in ovarian cancer. Their findings are published in the journal, PLOS ONE....

2014-02-26 23:22:59

The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013. BCC Research expects the market to grow to $954.3 million by 2018, and register a five-year compound annual growth rate of 21.4% from 2013 to 2018. Wellesley, Mass. (PRWEB) February 26, 2014 According to a new technical market research report Histone Deacetylase Inhibitors: Emerging Markets, from BCC Research (http://www.bccresearch.com), the...

2014-02-05 23:23:28

Repligen Corporation announced that BioMarin Pharmaceutical has acquired the assets in the company’s Histone DeACetylase (HDAC) inhibitor program. Downingtown, PA (PRWEB) February 05, 2014 Repligen Corporation announced that BioMarin Pharmaceutical has acquired the assets in the company’s Histone DeACetylase (HDAC) inhibitor program. Repligen has been advancing a therapeutic research and development program in Friedreich's Ataxia (FA) in which specific HDAC inhibitors have been...

PTSD Treatment Combines Psychotherapy And HDAC2 Inhibitor
2014-01-17 05:07:59

Rebekah Eliason for redOrbit.com - Your Universe Online Approximately eight million Americans are afflicted with post-traumatic stress disorder (PTSD). This condition is characterized by severe anxiety that can be traced back to a traumatic event such as a battle or violent attack. Because of the difficulties in treating this disorder with behavioral approaches, these traumatic memories often last throughout a lifetime. Although many patients are treated with psychotherapy in order to...

2013-11-27 13:19:32

A new study published 26th November in the open access journal PLOS Biology, identifies a new target in the search for therapeutic interventions for Huntington's disease – a devastating late-onset neurodegenerative disorder. The disease is genetic, affecting up to one person in 10,000, and from the age of about 35 leads to increasingly severe problems with movement, mental function, and behavior. Patients usually die within 20 years of onset, and there is to date no treatment that will...

2013-11-25 14:40:21

2 separate studies yield key findings for the prevention, diagnosis, treatment and cure for the disease Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.